Global Bioresorbable Scaffolds Market

Bioresorbable Scaffolds Market Size, Share, Growth Analysis, By Type(Drug Eluting Coronary Scaffolds, Sirolimus-Eluting Device, Everolimus-Eluting Device, Novolimus-Eluting Device), By Material(Absorbable Magnesium Stent (AMS), Polymeric Scaffold, Polycarbonate Scaffold, and Others), By Region - Industry Forecast 2024-2031

Report ID: SQMIG35A2472 | Region: Global | Published Date: March, 2024
Pages: 219 | Tables: 66 | Figures: 70

Bioresorbable Scaffolds Market News

  • In April 2023, Arterius announced that it appointed Gerard Harper as Chief Financial Officer. Arterius is a leading U.K.-based company that is developing innovative medical devices including next-generation bioresorbable peripheral stents. Gerard would help Arterius to develop and drive the commercial strategy for the successful launch of a suite of innovative technologies in its current pipeline.
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.



Bioresorbable Scaffolds Market size was valued at USD 374.94 million in 2022 and is poised to grow from USD 416.56 million in 2023 to USD 966.92 million by 2031, growing at a CAGR of 11.10% during the forecast period (2024-2031).

The competitive landscape of the bioresorbable scaffolds market encompasses comprehensive insights into each competitor. These insights encompass various aspects, including an overview of the company, its financial standing, revenue generation, market potential, research and development investments, novel market strategies, reach, production facilities, capacities, strengths, weaknesses, product launches, breadth of offerings, and dominant applications. Notably, the information provided pertains solely to the strategic direction of these companies in the context of the bioresorbable scaffolds market. 'Abbott', 'Medtronic', 'Boston Scientific Corporation', 'Biotronik', 'Elixir Medical Corporation', 'REVA Medical', 'Amaranth Medical', 'Kyoto Medical Planning', 'Xenogenics Corporation', 'B. Braun', 'Cardinal Health', 'Lombard Medical', 'Translumina', 'MicroPort Scientific Corporation', 'TERUMO CORPORATION'

The escalating prevalence of cardiovascular diseases, such as coronary artery disease and peripheral artery disease, is a major driver for the bioresorbable scaffolds market. These conditions necessitate advanced treatments to restore blood flow, creating a demand for innovative solutions like bioresorbable scaffolds.

Increasing elderly population requires frequent healthcare services, driving the demand for bioresorbable scaffolds as older individuals are more susceptible to cardiovascular diseases.

The dominance of the bioresorbable scaffolds market stands with North America, attributed to several factors such as a significant population affected with cardiovascular diseases, a multitude of prominent companies operating in the region, and an increasing elderly demographic. Moreover, the rise in obesity and diabetes cases, sedentary lifestyles, heightened stress levels, and desk-bound routines have collectively propelled market growth. Following the Americas, Europe holds the second-largest market share, trailed by the Asia Pacific region. Notably, Asia Pacific stands out as the rapidly growing market due to its swift technological advancements and a substantial patient pool grappling with various vascular disorders. On the other hand, the Middle East & Africa region accounts for the least share in the bioresorbable scaffolds market.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.


Feedback From Our Clients

Global Bioresorbable Scaffolds Market

Report ID: SQMIG35A2472